Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q77828160)
Watch
English
Non-randomised phase II trials of drug combinations: often meaningless, sometimes misleading. Are there alternative strategies?
scientific article published on 01 March 2002
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed ID
11916543
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11916543%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 December 2019
editorial
0 references
title
Non-randomised phase II trials of drug combinations: often meaningless, sometimes misleading. Are there alternative strategies?
(English)
1 reference
stated in
Europe PubMed Central
PubMed ID
11916543
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11916543%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 December 2019
main subject
phase II clinical trial
1 reference
based on heuristic
inferred from title
author name string
M Van Glabbeke
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed ID
11916543
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11916543%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 December 2019
W Steward
series ordinal
2
1 reference
stated in
Europe PubMed Central
PubMed ID
11916543
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11916543%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 December 2019
J P Armand
series ordinal
3
1 reference
stated in
Europe PubMed Central
PubMed ID
11916543
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11916543%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 December 2019
publication date
1 March 2002
1 reference
stated in
Europe PubMed Central
PubMed ID
11916543
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11916543%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 December 2019
published in
European Journal of Cancer
1 reference
stated in
Europe PubMed Central
PubMed ID
11916543
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11916543%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 December 2019
volume
38
1 reference
stated in
Europe PubMed Central
PubMed ID
11916543
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11916543%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 December 2019
issue
5
1 reference
stated in
Europe PubMed Central
PubMed ID
11916543
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11916543%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 December 2019
page(s)
635-638
1 reference
stated in
Europe PubMed Central
PubMed ID
11916543
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11916543%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 December 2019
cites work
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900419-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Statistical methodology of phase III cancer clinical trials: advances and future perspectives
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900419-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Gemcitabine, vinorelbine and cisplatin combination chemotherapy in advanced non-small cell lung cancer: a phase II trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900419-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Optimisation of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of hydroxyurea, leucovorin, 5-FU and cisplatin (HLFP regimen) for metastatic oesophageal cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900419-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Results of a randomised phase II study of cisplatin plus 5-fluorouracil versus cisplatin plus 5-fluorouracil with alpha-interferon in metastatic pancreatic cancer: an EORTC gastrointestinal tract cancer group trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900419-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900419-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD)
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900419-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900419-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The m-BACOD combination chemotherapy regimen in large-cell lymphoma: analysis of the completed trial and comparison with the M-BACOD regimen
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900419-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: a groupwide Southwest Oncology Group study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900419-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900419-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900419-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900419-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
CHOP vs. ProMACE-CytaBOM in the treatment of aggressive non-Hodgkin's lymphomas: long-term results of a multicenter randomized trial.(PETHEMA: Spanish Cooperative Group for the Study of Hematological Malignancies Treatment, Spanish Society of Hemato
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900419-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Treatment of diffuse large-cell lymphoma: a summary of outcome for patients treated by Southwest Oncology Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900419-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900419-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900419-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900419-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900419-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The controversy over high-dose chemotherapy with autologous bone marrow transplant for breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900419-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
An on-site audit of the South African trial of high-dose chemotherapy for metastatic breast cancer and associated publications.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900419-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900419-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A critique of the eleven randomised trials of high-dose chemotherapy for breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900419-1
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S0959-8049(01)00419-1
1 reference
stated in
Europe PubMed Central
PubMed ID
11916543
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11916543%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 December 2019
PubMed ID
11916543
1 reference
stated in
Europe PubMed Central
PubMed ID
11916543
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11916543%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 December 2019
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit